GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected from Activation-induced Cell Death by PD-1 Blockade

Molecular Therapy

Volumn 24, Issue 6, 2016, Pages 1135-1149

  Gargett, Tessa ^a   Yu, Wenbo ^a   Dotti, Gianpietro ^b,c   Yvon, Eric S ^b,d   Christo, Susan N ^a   Hayball, John D ^a,e,f   Lewis, Ian D ^f   Brenner, Malcolm K ^b   Brown, Michael P ^a,f,g  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b HOUSTON METHODIST HOSPITAL   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e UNIVERSITY OF ADELAIDE   (Australia)

^f UNIVERSITY OF ADELAIDE   (Australia)

^g ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; GANGLIOSIDE GD2; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; GANGLIOSIDE; LYMPHOCYTE ANTIGEN RECEPTOR; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN;

ARTICLE; CELL DEATH; CELL SURVIVAL; CELL THERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HUMAN; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; PROTEIN EXPRESSION; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DRUG EFFECTS; DRUG SCREENING; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MELANOMA; METABOLISM; METASTASIS; MOUSE; PHASE 1 CLINICAL TRIAL; T LYMPHOCYTE; TRANSPLANTATION; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL LINE, TUMOR; CELL SURVIVAL; GANGLIOSIDES; HUMANS; LYMPHOCYTE ACTIVATION; MELANOMA; MICE; NEOPLASM METASTASIS; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84964317521     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2016.63     Document Type: Article

References (52)

1. Porter, DL, Levine, BL, Kalos, M, Bagg, A and June, CH (2011). Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365: 725-733.
2. Grupp, SA, Kalos, M, Barrett, D, Aplenc, R, Porter, DL, Rheingold, SR et al. (2013). Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368: 1509-1518.
3. Kershaw, MH, Westwood, JA, Parker, LL, Wang, G, Eshhar, Z, Mavroukakis, SA et al. (2006). A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 12(20 Pt 1): 6106-6115.
4. Louis, CU, Savoldo, B, Dotti, G, Pule, M, Yvon, E, Myers, GD et al. (2011). Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118: 6050-6056.
5. Lamers, CH, Sleijfer, S, van Steenbergen, S, van Elzakker, P, van Krimpen, B, Groot, C et al. (2013). Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther 21: 904-912.
6. Zhu, Y, Tan, Y, Ou, R, Zhong, Q, Zheng, L, Du, Y et al. (2015). Anti-CD19 chimeric antigen receptor-modified T cells for B-cell malignancies: A systematic review of efficacy and safety in clinical trials. Eur J Haematol 96: 389-396.
7. Pule, MA, Savoldo, B, Myers, GD, Rossig, C, Russell, HV, Dotti, G et al. (2008). Virusspecific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 14: 1264-1270.
8. Lamers, CH, Willemsen, R, van Elzakker, P, van Steenbergen-Langeveld, S, Broertjes, M, Oosterwijk-Wakka, J et al. (2011). Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood 117: 72-82.
9. Jensen, MC, Popplewell, L, Cooper, LJ, DiGiusto, D, Kalos, M, Ostberg, JR et al. (2010). Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant 16: 1245-1256.
10. Künkele, A, Johnson, AJ, Rolczynski, LS, Chang, CA, Hoglund, V, Kelly-Spratt, KS et al. (2015). Functional tuning of CARs reveals signaling threshold above which CD8+ CTL antitumor potency is attenuated due to cell Fas-FasL-dependent AICD. Cancer Immunol Res 3: 368-379.
11. Hudecek, M, Sommermeyer, D, Kosasih, PL, Silva-Benedict, A, Liu, L, Rader, C et al. (2015). The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol Res 3: 125-135.
12. Hombach, A, Hombach, AA and Abken, H (2010). Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target' activation and unintended initiation of an innate immune response. Gene Ther 17: 1206-1213.
13. Green, DR, Droin, N and Pinkoski, M (2003). Activation-induced cell death in T cells. Immunol Rev 193: 70-81.
14. Mehrotra, S, Chhabra, A, Chattopadhyay, S, Dorsky, DI, Chakraborty, NG and Mukherji, B (2004). Rescuing melanoma epitope-specific cytolytic T lymphocytes from activation-induced cell death, by SP600125, an inhibitor of JNK: implications in cancer immunotherapy. J Immunol 173: 6017-6024.
15. Maher, S, Toomey, D, Condron, C and Bouchier-Hayes, D (2002). Activation-induced cell death: the controversial role of Fas and Fas ligand in immune privilege and tumour counterattack. Immunol Cell Biol 80: 131-137.
16. Chhabra, A (2010). Mitochondria-centric activation induced cell death of cytolytic T lymphocytes and its implications for cancer immunotherapy. Vaccine 28: 4566-4572.
17. Hombach, AA, Rappl, G and Abken, H (2013). Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 "superstimulation". Mol Ther 21: 2268-2277.
18. Speiser, DE, Utzschneider, DT, Oberle, SG, Münz, C, Romero, P and Zehn, D (2014). T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion? Nat Rev Immunol 14: 768-774.
19. Matsuzaki, J, Gnjatic, S, Mhawech-Fauceglia, P, Beck, A, Miller, A, Tsuji, T et al. (2010). Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci USA 107: 7875-7880.
20. Tumeh, PC, Harview, CL, Yearley, JH, Shintaku, IP, Taylor, EJ, Robert, L et al. (2014). PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515: 568-571.
21. John, LB, Devaud, C, Duong, CP, Yong, CS, Beavis, PA, Haynes, NM et al. (2013). Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res 19: 5636-5646.
22. Long, AH, Haso, WM, Shern, JF, Wanhainen, KM, Murgai, M, Ingaramo, M et al. (2015). 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med 21: 581-590.
23. Gargett, T and Brown, MP (2015). Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2. Cytotherapy 17: 487-495.
24. Kaiser, AD, Schuster, K, Gadiot, J, Borkner, L, Daebritz, H, Schmitt, C et al. (2012). Reduced tumor-antigen density leads to PD-1/PD-L1-mediated impairment of partially exhausted CD8T cells. Eur J Immunol 42: 662-671.
25. Leitner, J, Rieger, A, Pickl, WF, Zlabinger, G, Grabmeier-Pfistershammer, K and Steinberger, P (2013). TIM-3 does not act as a receptor for galectin-9. PLoS Pathog 9: e1003253.
26. Frigault, MJ, Lee, J, Basil, MC, Carpenito, C, Motohashi, S, Scholler, J et al. (2015). Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. Cancer Immunol Res 3: 356-367.
27. Gargett, T, Fraser, CK, Dotti, G, Yvon, ES and Brown, MP (2015). BRAF and MEK inhibition variably affect GD2-specific chimeric antigen receptor (CAR) T-cell function in vitro. J Immunother 38: 12-23.
28. Hoyos, V, Savoldo, B, Quintarelli, C, Mahendravada, A, Zhang, M, Vera, J et al. (2010). Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia 24: 1160-1170.
29. Pulko, V, Harris, KJ, Liu, X, Gibbons, RM, Harrington, SM, Krco, CJ et al. (2011). B7-h1 expressed by activated CD8 T cells is essential for their survival. J Immunol 187: 5606-5614.
30. Gibbons, RM, Liu, X, Pulko, V, Harrington, SM, Krco, CJ, Kwon, ED et al. (2012). B7-H1 limits the entry of effector CD8(+) T cells to the memory pool by upregulating Bim. Oncoimmunology 1: 1061-1073.
31. Pulè, MA, Straathof, KC, Dotti, G, Heslop, HE, Rooney, CM and Brenner, MK (2005). A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther 12: 933-941.
32. Yvon, E, Del Vecchio, M, Savoldo, B, Hoyos, V, Dutour, A, Anichini, A et al. (2009). Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells. Clin Cancer Res 15: 5852-5860.
33. Di Stasi, A, Tey, SK, Dotti, G, Fujita, Y, Kennedy-Nasser, A, Martinez, C et al. (2011). Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 365: 1673-1683.
34. Gargett, T and Brown, MP (2014). The inducible caspase-9 suicide gene system as a "safety switch" to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. Front Pharmacol 5: 235.
35. Wherry, EJ (2011). T cell exhaustion. Nat Immunol 12: 492-499.
36. Herbst, RS, Soria, JC, Kowanetz, M, Fine, GD, Hamid, O, Gordon, MS et al. (2014). Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515: 563-567.
37. Xu, Y, Zhang, M, Ramos, CA, Durett, A, Liu, E, Dakhova, O et al. (2014). Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood 123: 3750-3759.
38. Barrett, DM, Singh, N, Liu, X, Jiang, S, June, CH, Grupp, SA et al. (2014). Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy. Cytotherapy 16: 619-630.
39. Lugli, E, Gattinoni, L, Roberto, A, Mavilio, D, Price, DA, Restifo, NP et al. (2013). Identification, isolation and in vitro expansion of human and nonhuman primate T stem cell memory cells. Nat Protoc 8: 33-42.
40. Latchman, Y, Wood, CR, Chernova, T, Chaudhary, D, Borde, M, Chernova, I et al. (2001). PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2: 261-268.
41. Butte, MJ, Keir, ME, Phamduy, TB, Sharpe, AH and Freeman, GJ (2007). Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27: 111-122.
42. Chemnitz, JM, Parry, RV, Nichols, KE, June, CH and Riley, JL (2004). SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol 173: 945-954.
43. Amarnath, S, Mangus, CW, Wang, JC, Wei, F, He, A, Kapoor, V et al. (2011). The PDL1-PD1 axis converts human TH1 cells into regulatory T cells. Sci Transl Med 3: 111ra120.
44. Ishida, Y, Agata, Y, Shibahara, K and Honjo, T (1992). Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11: 3887-3895.
45. Dong, H, Strome, SE, Salomao, DR, Tamura, H, Hirano, F, Flies, DB et al. (2002). Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med 8: 793-800.
46. Latchman, YE, Liang, SC, Wu, Y, Chernova, T, Sobel, RA, Klemm, M et al. (2004). PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci USA 101: 10691-10696.
47. Rowe, JH, Johanns, TM, Ertelt, JM and Way, SS (2008). PDL-1 blockade impedes T cell expansion and protective immunity primed by attenuated Listeria monocytogenes. J Immunol 180: 7553-7557.
48. Azuma, T, Yao, S, Zhu, G, Flies, AS, Flies, SJ and Chen, L (2008). B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 111: 3635-3643.
49. Zhao, Z, Condomines, M, van der Stegen, SJ, Perna, F, Kloss, CC, Gunset, G et al. (2015). Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell 28: 415-428.
50. Klebanoff, CA, Khong, HT, Antony, PA, Palmer, DC and Restifo, NP (2005). Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol 26: 111-117.
51. Nagamatsu, T, Schust, DJ, Sugimoto, J and Barrier, BF (2009). Human decidual stromal cells suppress cytokine secretion by allogenic CD4+ T cells via PD-1 ligand interactions. Hum Reprod 24: 3160-3171.
52. Meli, M, D'Alessandro, N, Tolomeo, M, Rausa, L, Notarbartolo, M and Dusonchet, L (2003). NF-kappaB inhibition restores sensitivity to Fas-mediated apoptosis in lymphoma cell lines. Ann N Y Acad Sci 1010: 232-236.